COMPASS Pathways plc (NasdaqGS: CMPS)
Health Care · Biotechnology · GB
$11.59
-3.46% today · +86.3% 1Y
COMPASS Pathways plc (NasdaqGS: CMPS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.66B and employs 156 people.
Over the last twelve months the share price has gained 86.3%, trading between 4.88 and 15.87.
Tweenvest scores COMPASS Pathways plc across four factors: quality 35/100, value 57/100. Its strongest factor is value.
CMPS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.66B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -3.61
- Dividend yield
- —
- Beta (5Y)
- 2.56
- 52-week high
- $15.87
- 52-week low
- $4.88
- Avg volume (3M)
- —
- Shares outstanding
- 138.48M
- Employees
- 156
- Next earnings
- —
About COMPASS Pathways plc
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
- ISIN
- US20451W1018
- Founded
- 2020
- Listed since
- Sep 18, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Yantai Dongcheng Pharmaceutical Group Co.,Ltd.SZSE: 002675 | $1.71B | CN¥13.89 | +7.67% |
| Freenome, Inc.NasdaqCM: FRNM | $1.70B | $15.78 | -3.31% |
| PYC Therapeutics LimitedASX: PYC | $1.68B | AU$2.45 | -0.41% |
| Novoprotein Scientific Inc.SHSE: 688137 | $1.67B | CN¥161.18 | +0.49% |
| Stoke Therapeutics, Inc.NasdaqGS: STOK | $1.60B | $24.45 | -1.17% |
| Mabwell (Shanghai) Bioscience Co., Ltd.SHSE: 688062 | $1.60B | CN¥24.78 | -8.36% |
| uniQure N.V.NasdaqGS: QURE | $1.57B | $21.73 | -3.81% |
| Ultragenyx Pharmaceutical Inc.NasdaqGS: RARE | $1.52B | $15.28 | -1.29% |
Figures last refreshed Oct 11, 2026.